PTPN11 and myeloproliferative disorder: Furthermore, activating mutations SHP2 in the bone marrow microenvironment, but not in the tumor cells, also promote childhood MPN development and progression through detrimental effects on hematopoietic stem cells (HSCs) in non-autonomous mechanism (Dong et al., 2016).